MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$226,863K
Free Cash flow
-$44,266K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities and sal...
Stock-based compensation
Accounts payable and accrued exp...
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Prepaid expenses and other asset...
Accounts payable and accrued exp...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-55,436
-56,211
-37,386
-36,330
Stock-based compensation
8,238
5,858
4,449
3,614
Depreciation
44
44
43
24
Non-cash lease expense
277
273
297
249
Net amortization of premiums and discounts on marketable securities
-237
-338
-269
-32
Prepaid expenses and other assets
1,400
-2,089
-839
301
Accounts payable and accrued expenses-Nonrelated Party
4,961
11,725
6,423
3,949
Accounts payable and accrued expenses-Related Party
-850
-1,354
1,472
-168
Operating lease liabilities
-277
-270
-292
-317
Net cash used in operating activities
-44,206
-37,508
-23,886
-29,248
Purchase of marketable securities
244,929
-
-
-
Purchases of marketable securities
-
-
82,094
236,079
Proceeds from maturities and sales of marketable securities
60,000
101,000
-
-
Purchase of property and equipment
60
60
238
42
Proceeds from sale of property and equipment
-
-
0
0
Net cash used in investing activities
-184,989
100,940
-82,332
-236,121
Proceeds from issuance of common stock and accompanying pre-funded warrants, net of issuance costs
0
161,763
29,498
0
Proceeds from exercise of options
2,332
1,582
1,732
436
Net cash provided by financing activities
2,332
163,345
31,230
436
Net decrease in cash and cash equivalents
-226,863
226,777
-74,988
-264,933
Cash and cash equivalents at beginning of period
323,462
96,685
171,673
489,711
Cash and cash equivalents at end of period
96,599
323,462
96,685
171,673
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
options
$2,332K
(291.93%↑ Y/Y)
Net cash provided by
financing activities
$2,332K
(291.93%↑ Y/Y)
Net decrease in cash
and cash...
-$226,863K
(-327.20%↓ Y/Y)
Canceled cashflow
$2,332K
Proceeds from maturities
and sales of...
$60,000K
Stock-based compensation
$8,238K
(18.65%↑ Y/Y)
Accounts payable and
accrued...
$4,961K
(282.73%↑ Y/Y)
Non-cash lease expense
$277K
(-20.63%↓ Y/Y)
Net amortization of
premiums and discounts on...
-$237K
Depreciation
$44K
(15.79%↑ Y/Y)
Net cash used in
investing activities
-$184,989K
Net cash used in
operating activities
-$44,206K
(17.68%↑ Y/Y)
Canceled cashflow
$60,000K
Canceled cashflow
$13,757K
Purchase of marketable
securities
$244,929K
Net loss
-$55,436K
(13.70%↑ Y/Y)
Purchase of property and
equipment
$60K
Prepaid expenses and
other assets
$1,400K
(129.52%↑ Y/Y)
Accounts payable and
accrued...
-$850K
(-156.70%↓ Y/Y)
Operating lease
liabilities
-$277K
(14.24%↑ Y/Y)
Buy us a coffee
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)